• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

4-(N-芳基)胺基-6-长链烷氧基取代蝶啶类化合物的合成及其抗肿瘤活性

林锦, 王旭, 王艰, 许秀枝, 陈垚昊, 李柱来

林锦, 王旭, 王艰, 许秀枝, 陈垚昊, 李柱来. 4-(N-芳基)胺基-6-长链烷氧基取代蝶啶类化合物的合成及其抗肿瘤活性[J]. 中国药科大学学报, 2018, 49(1): 64-71. DOI: 10.11665/j.issn.1000-5048.20180109
引用本文: 林锦, 王旭, 王艰, 许秀枝, 陈垚昊, 李柱来. 4-(N-芳基)胺基-6-长链烷氧基取代蝶啶类化合物的合成及其抗肿瘤活性[J]. 中国药科大学学报, 2018, 49(1): 64-71. DOI: 10.11665/j.issn.1000-5048.20180109
LIN Jin, WANG Xu, WANG Jian, XU Xiuzhi, CHEN Yaohao, LI Zhulai. Synthesis and antitumor activities of 4-(N-aryl)amino-6-long chain alkoxy pteridine derivatives[J]. Journal of China Pharmaceutical University, 2018, 49(1): 64-71. DOI: 10.11665/j.issn.1000-5048.20180109
Citation: LIN Jin, WANG Xu, WANG Jian, XU Xiuzhi, CHEN Yaohao, LI Zhulai. Synthesis and antitumor activities of 4-(N-aryl)amino-6-long chain alkoxy pteridine derivatives[J]. Journal of China Pharmaceutical University, 2018, 49(1): 64-71. DOI: 10.11665/j.issn.1000-5048.20180109

4-(N-芳基)胺基-6-长链烷氧基取代蝶啶类化合物的合成及其抗肿瘤活性

基金项目: 福建省科技创新联合资金资助项目(No.2016Y9052);福建省高校杰出青年科研人才培育计划资助项目(No.2017B021) #林锦和王旭对本文的贡献相同

Synthesis and antitumor activities of 4-(N-aryl)amino-6-long chain alkoxy pteridine derivatives

  • 摘要: 采用具有喹唑啉为母核的抗肿瘤药物作为先导化合物,利用生物电子等排原理,设计并合成一系列4-(N-芳基)胺基-6-长链烷氧基取代蝶啶类化合物 7a ~ 7l ,并利用MTT法测试其对A549、KG1a和HGC-27肿瘤细胞的增殖抑制作用。以3-氨基吡嗪-2-羧酸甲酯为起始底物,通过6步反应合成12种目标化合物( 7a ~ 7l )并确证其结构(1H NMR、13C NMR、MS)。生物活性试验表明,蝶啶4位为2-氯-5-硝基苯胺基取代时,其活性均高于其他苯胺基取代的产物。化合物 7b 对A549的活性(IC50=11.55 μmol/L)与阳性对照物吉非替尼(IC50=5.95 μmol/L)十分接近;化合物 7k 对3组细胞的IC50均十分接近对照物吉非替尼。由于筛选出的化合物均有2-氯-5-硝基苯胺基片段,可以此结构为基础进行深入研究。
    Abstract: A series of 4-(N-aryl)amino-6-alkoxyl pteridine derivatives was designed and synthesized via the bioisostere principle using anti-cancer drugs with quinazoline cores as lead compounds. The proliferative inhibitory activities of the synthesized compounds against tumor cells A549, KG1a and HGC-27 were also performed by MTT assay. Using methyl 3-aminopyrazine-2-carboxylate as the starting material, 12 target compounds( 7a - 7l )were synthesized through six-step reaction, and characterized by 1H NMR, 13C NMR and MS. It was showed that antitumor activity of pteridines with 2-chloro-5-nitro-anilino substituted in position 4 was more potent than that of others. The activity of compound 7b on A549 cells(IC50=11. 55 μmol/L)was closely approximate to that of positive control gefitinib(IC50=5. 95 μmol/L). IC50 values of compound 7k on three cell lines were all close to those of gefitinib. A 2-chloro-5-nitro-anilino fragment was contained in preferred compounds which might be modified for further investigation.
  • [1] Gschwind A,Fischer OM,Ullrich A.The discovery of receptor tyrosine kinases targets for cancer therapy[J].Nat Rev Cancer,2004,4(5):361-370.
    [2] Chahrour O,Cairns D,Omran Z.Small moleculekinase inhibitors as anti-cancer therapeutics[J].Mini Rev Med Chem,2012,12(5):399-411.
    [3] Zhou W,Liu X,Tu Z,et al.Discovery of pteridin-7(8H)-onebased irreversible inhibitors targeting the epidermal growth factor receptor(EGFR)kinase T790M/L858R mutant[J].J Med Chem,2013,56(20):7821-7837.
    [4] Sun D,Yang Y,Lyu J,et al.Discovery and rational design of pteridin-7(8H)-one-based inhibitors targeting FMS-like tyrosine kinase 3(FLT3)and its mutants[J].J Med Chem,2016,59(13):6187-6200.
    [5] Ellingson RC,Henry R,McDonald FG,et al.Derivatives 3-aminopyrazinoic acid[J].J Am Chem Soc,1945,67(10):1711-1713.
    [6] Albert A,Ohta K,Studies P,et al.New routes to 4-aminopteridines via 3-(dimethylaminomethyleneamino)pyrazine-2-carbonitrile and related compounds[J].J Chem Soc,1971,22:3727-3730.
    [7] Li MD.Design,Synthesis and structure-activity-relation study of novel anti-cancer compounds targeted on protein tyrosine kinase(作用于酪氨酸激酶的抗肿瘤小分子抑制剂的设计与合成)[D].Nanjing:Southeast University,2007.
    [8] Duan C,Jia J,Zhu R,Wang J.Synthesis of N-substituted-6-alkoxypteridin-4-amine[J].J Het Chem,2012,49(4):865-872.
    [9] Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors[J].Pharmacol Ther,1999,82(2/3):195-206.
    [10] Lawrence DS,Niu J.Protein kinase inhibitors:the tyrosine-specific protein kinases[J].Pharmacol Ther,1998,77(2):81-114.
    [11] Stamos J,Sliwlowski MX,Eigenbrot C.Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor[J].J Biol Chem,2002,277(48):46265-46272.
    [12] Sun J,Li D,Li J,et al.Design,synthesis,biological evaluation,and molecular modeling study of 4-alkoxyquinazoline derivatives as potential VEGFR2 kinase inhibitors[J].Org Biomol Chem,2013,11(44):7676-7686.
    [13] Qin X,Li Z,Yang L,et al.Discovery of new[1,4] dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant[J].Bioorg Med Chem,2016,24(13):2871-2881.
    [14] Debnath AK,Hansch C.Structure-activity relationship of genotoxic polycyclic aromatic nitro compounds:further evidence for the importance of hydrophobicity and molecular orbital energies in genetic toxicity[J].Environ Mol Mutagen,1992,20(2):140-144.
计量
  • 文章访问数:  880
  • HTML全文浏览量:  0
  • PDF下载量:  1092
  • 被引次数: 0
出版历程
  • 刊出日期:  2018-02-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭